Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

41. Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies

Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies 29615487 2018 04 04 1468-3288 2018 Apr 03 Gut Gut Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies. gutjnl-2017 (...) -315730 10.1136/gutjnl-2017-315730 To systematically identify and validate published colorectal cancer risk prediction models that do not require invasive testing in two large population-based prospective cohorts. Models were identified through an update of a published systematic review and validated in the European Prospective Investigation into Cancer and Nutrition (EPIC) and the UK Biobank. The performance of the models to predict the occurrence of colorectal cancer within 5 or 10 years after study

EvidenceUpdates2018

42. Combination drug development in BRAF mutant colorectal cancer

Combination drug development in BRAF mutant colorectal cancer 29854866 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Combination drug development in BRAF mutant colorectal cancer. 51-53 10.18632/oncoscience.399 Lam Michael M Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University (...) of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, Texas 77030, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF mutant colorectal cancer ERK MEK combinations resistance CONFLICTS OF INTEREST The authors declare

Oncoscience2018 Full Text: Link to full Text with Trip Pro

43. Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer

Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer 29854868 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer. 57-58 10.18632/oncoscience.401 Gao Chenxi C Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Hu Jing J Department (...) of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF CRC FAK resistance the Wnt/b-catenin pathway CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 16 2018 04 16 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854868 10.18632/oncoscience.401 401 PMC5978442 Sci Signal. 2012 Jan 10;5(206):ra3 22234612 Proc Natl Acad

Oncoscience2018 Full Text: Link to full Text with Trip Pro

44. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se 29713498 2018 11 14 2059-7029 3 3 2018 ESMO open ESMO Open Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses (...) of the RAISE trial and validation in an electronic medical record data set. e000347 10.1136/esmoopen-2018-000347 In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. Thus, we conducted an exploratory post-hoc analysis

ESMO open2018 Full Text: Link to full Text with Trip Pro

45. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial.

Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Background: The long-term effects of sigmoidoscopy screening on colorectal cancer (CRC) incidence and mortality in women and men are unclear. Objective: To determine the effectiveness of flexible sigmoidoscopy screening after 15 years of follow-up in women and men. Design: Randomized controlled trial. (ClinicalTrials.gov: NCT00119912 ). Setting: Oslo and Telemark (...) : Offering sigmoidoscopy screening in Norway reduced CRC incidence and mortality in men but had little or no effect in women. Primary Funding Source: Norwegian government and Norwegian Cancer Society.

Annals of Internal Medicine2018

46. ColonFlag for identifying people at risk of colorectal cancer

ColonFlag for identifying people at risk of colorectal cancer ColonFlag for identifying people at risk of ColonFlag for identifying people at risk of colorectal cancer colorectal cancer Medtech innovation briefing Published: 12 April 2018 nice.org.uk/guidance/mib142 pathways Summary Summary The technology technology described in this briefing is ColonFlag. It uses routinely available datasets to help identify people who are at high risk of developing colorectal cancer. The inno innovativ vative (...) aspects e aspects are that ColonFlag uses so-called big data and machine learning methods. The intended place in ther place in therap apy y would be as an addition to current investigations, such as faecal immunochemical tests, to help identify people who may need referral for suspected colorectal cancer. The main points from the e main points from the evidence vidence summarised in this briefing are from 4 observational studies including nearly 3.5 million patient records. They show that ColonFlag

National Institute for Health and Clinical Excellence - Advice2018

47. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee or endorsement

Cystic Fibrosis Foundation2018

48. New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer

New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer 29337636 2018 02 14 1527-7755 36 6 2018 Feb 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer. 609-616 10.1200/JCO.2017.74.9739 Purpose We sought to determine the long-term risk of cardiovascular disease (CVD)-stroke and myocardial infarction-and congestive (...) heart failure (CHF) in older patients with colorectal cancer, as well as to understand the roles that preexisting comorbidities and cancer therapy play in increasing this risk. Patients and Methods We evaluated individuals from the SEER-Medicare database with incident stage I to III colorectal cancer at age older than 65 years between January 1, 2000, and December 31, 2011 (n = 72,408) and compared these patients with a matched cohort of Medicare patients without cancer (n = 72,408). Results Median

EvidenceUpdates2018

49. Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer

Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer 29146523 2018 04 07 1528-0012 154 4 2018 03 Gastroenterology Gastroenterology Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer. 906-915.e7 S0016-5085(17)36351-5 10.1053/j.gastro.2017.11.005 Previous studies reported that black vs white disparities in survival among elderly patients with colorectal cancer (CRC) were because of differences (...) 11870160 J Clin Epidemiol. 2001 Apr;54(4):359-66 11297886 Ann Surg Oncol. 2013 Oct;20(11):3363-9 23771247 Clin Colorectal Cancer. 2013 Dec;12(4):287-93 24188687 Cancer. 2011 Sep 15;117(18):4267-76 21413000 Am J Gastroenterol. 2005 Mar;100(3):515-23; discussion 514 15743345 Med Care. 1996 Sep;34(9):970-84 8792784 PLoS One. 2014 Jun 23;9(6):e100461 24956473 J Natl Cancer Inst. 2017 Aug 1;109 (8): 28376186 Gastroenterology. 2016 May;150(5):1135-1146 26836586 CA Cancer J Clin. 2017 Jan;67(1):7-30 28055103

EvidenceUpdates2018

50. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) 29346040 2018 02 26 1527-7755 36 7 2018 Mar 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). 674-681 10.1200/JCO.2017.75.2931 (...) Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. Patients and Methods In this open-label, phase III, randomized controlled trial, we compared the tumor control duration (TCD) observed with bevacizumab maintenance and with no treatment (observation) during CFI subsequent to induction chemotherapy with 12 cycles of fluorouracil, leucovorin, and irinotecan plus

EvidenceUpdates2018

51. Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery

Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery 29174927 2018 04 07 1528-0012 154 4 2018 03 Gastroenterology Gastroenterology Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery. 927-934.e4 S0016-5085(17)36383-7 10.1053/j.gastro.2017.11.025 Recommendations for surveillance after curative surgery for colorectal cancer (CRC) include a 1-year post-resection abdominal-pelvic computed tomography (CT) scan (...) and optical colonoscopy (OC). CT colonography (CTC), when used in CRC screening, effectively identifies colorectal polyps ≥10 mm and cancers. We performed a prospective study to determine whether CTC, concurrent with CT, could substitute for OC in CRC surveillance. Our study enrolled 231 patients with resected stage 0-III CRC, identified at 5 tertiary care academic centers. Approximately 1 year after surgery, participants underwent outpatient CTC plus CT, followed by same-day OC. CTC results were

EvidenceUpdates2018

52. Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016

Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 29636987 2018 11 14 2059-7029 3 3 2018 ESMO open ESMO Open Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016. e000315 10.1136/esmoopen-2017-000315 Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean (...) , it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each

ESMO open2018 Full Text: Link to full Text with Trip Pro

53. Improving Internal Medicine Residents’ Colorectal Cancer Screening Knowledge Using a Smartphone App: Pilot Study

Improving Internal Medicine Residents’ Colorectal Cancer Screening Knowledge Using a Smartphone App: Pilot Study Colo-Rectal Cancer Screening Survey I am Zubair Khan MD. from the University of Toledo Internal Medicine Residency. I am conducting a survey with my colleagues on the “Internal Medicine Residents Knowledge of Colorectal Cancer Screening before and after Educational Strategies (including development of a smart phone application) as assessed by a web based survey”. The survey (...) . There are minimal risks associated with this survey, such as the stress of completing survey. Taking part in this survey is your agreement to participate. If you have any questions regarding the survey, contact Zubair Khan MD, Internal Medicine Residency, zubair.khan@utoledo.edu [UT IRB# 201713] ? I agree to Participate in the survey. ? I don't want to participate in the survey. 2. What is your PGY level? PGY 1 PGY 2 PGY 3 3. For average risk patients at what age you start Colorectal Cancer screening ? 40 Years

JMIR medical education2018 Full Text: Link to full Text with Trip Pro

54. Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial.

Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Background: Screening for colorectal cancer (CRC) reduces mortality, yet more than one third of age-eligible Americans are unscreened. Objective: To examine the effect of a digital health intervention, Mobile Patient Technology for Health-CRC (mPATH-CRC), on rates of CRC screening. Design: Randomized clinical trial. (ClinicalTrials.gov: NCT02088333 ). Setting (...) identify methods for implementing similar interventions in clinical care. Primary Funding Source: National Cancer Institute.

Annals of Internal Medicine2018 Full Text: Link to full Text with Trip Pro

55. Colonoscopy and Colorectal Cancer Mortality in the Veterans Affairs Health Care System: A Case-Control Study.

Colonoscopy and Colorectal Cancer Mortality in the Veterans Affairs Health Care System: A Case-Control Study. Background: Colonoscopy is widely used in the Veterans Affairs (VA) health care system for colorectal cancer (CRC) prevention, but its effect on CRC mortality is unknown. Objective: To determine whether colonoscopy is associated with decreased CRC mortality in veterans and whether its effect differs by anatomical location of CRC. Design: Case-control study. Setting: VA-Medicare (...) was associated with reduced mortality for left-sided cancer (OR, 0.28 [CI, 0.24 to 0.32]) and right-sided cancer (OR, 0.54 [CI, 0.47 to 0.63]). The results were similar for patients who had undergone screening colonoscopy (overall OR, 0.30 [CI, 0.24 to 0.38]). Sensitivity analyses that varied the interval between CRC diagnosis and colonoscopy exposure did not affect the primary findings. Limitation: Unmeasured confounding. Conclusion: In this study using national VA-Medicare data, colonoscopy was associated

Annals of Internal Medicine2018

56. The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients

The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients Biomedicines | Free Full-Text | The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients Next Article in Journal Previous Article in Journal Choose your preferred view mode Please select whether you prefer to view the MDPI pages with a view tailored for mobile displays or to view the MDPI pages in the normal (...) by Authors Export Article Create a SciFeed alert for new publications With following keywords gene expression profiling (GEP) lymph node metastasis (LNM) colorectal cancer (CRC) By following authors Noshad Peyravian Pegah Larki Ehsan Gharib Ehsan Nazemalhosseini-Mojarad Fakhrosadate Anaraki Chris Young James McClellan Maziar Ashrafian Bonab Hamid Asadzadeh-Aghdaei Mohammad Reza Zali Email: Freq: One email with all search results One email for each search /ajax/scifeed/subscribe MOL Viewer Open Access

Biomedicines2018 Full Text: Link to full Text with Trip Pro

57. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study 29215955 2018 01 29 1527-7755 36 4 2018 Feb 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian (...) Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. 350-358 10.1200/JCO.2017.74.3245 Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) in a phase II Japanese trial. This regional trial evaluated the efficacy and safety of trifluridine/tipiracil in Asian patients with mCRC with or without exposure to biologic therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase III trial was conducted

EvidenceUpdates2018

58. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes 29382774 2018 01 31 1468-3288 2018 Jan 30 Gut Gut Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. gutjnl-2017-315664 10.1136/gutjnl-2017-315664 Tumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair (dMMR (...) ) are determinants of prognosis in colorectal cancer. Although highly correlated, evidence suggests that these are independent predictors of outcome. However, the prognostic significance of combined TIL/MMR classification and how this compares to the major genomic and transcriptomic subtypes remain unclear. A prospective cohort of 1265 patients with stage II/III cancer was examined for TIL/MMR status and BRAF / KRAS mutations. Consensus molecular subtype (CMS) status was determined for 142 cases. Associations

EvidenceUpdates2018

59. Nivolumab (Opdivo) - metastatic colorectal cancer

Nivolumab (Opdivo) - metastatic colorectal cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 26 January 2018 EMA/51006/2018 EMEA/H/C/003985/II/0030 Withdrawal of the application for a change to the marketing authorisation (...) for Opdivo (nivolumab) On 13 December 2017, Bristol-Myers Squibb Pharma EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application to extend the use of Opdivo to treat colorectal cancer. What is Opdivo? Opdivo is a cancer medicine that contains the active substance nivolumab and is available as a concentrate that is made up into a solution for infusion (drip) into a vein. Opdivo has been authorised since June 2015. It is already used

European Medicines Agency - EPARs2018

60. Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer

Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer 1 Vardy JL, et al. ESMO Open 2018;3:e000302. doi:10.1136/esmoopen-2017-000302 Open Access Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer Janette L Vardy, 1 Haryana Mary Dhillon, 1 Gregory R Pond, 2 Corrinne Renton, 1 Stephen J Clarke, 1 Ian F Tannock 3 Original research To cite (...) : Vardy JL, Dhillon HM, Pond GR, et al. Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. ESMO Open 2018;3:e000302. doi:10.1136/ esmoopen-2017-000302 Received 1 December 2017 Revised 17 January 2018 Accepted 18 January 2018 1 University of Sydney, Sydney, New South Wales, Australia 2 McMaster University, Hamilton, Ontario, Canada 3 Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada Correspondence

ESMO open2018 Full Text: Link to full Text with Trip Pro